Publications from the GLASS Consortium

Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell, 2022. DOI:10.1016/j.cell.2022.04.038

iGLASS: imaging integration into the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2020. DOI:10.1093/neuonc/noaa160

Longitudinal molecular trajectories of diffuse glioma patients. Nature, 2019. DOI: 10.1038/s41586-019-1775-1

Commentary: The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas. Ashwin Narayanan, Sevin Turcan. Cell, 2020. DOI:10.1016/j.cell.2020.01.016.

Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro-Oncology, 2018. DOI:10.1093/neuonc/noy020

A non-exhaustive list of publications in which GLASS data were used:

Alghamri et al. Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1. Neurooncol Adv. 2020 Mar 27;2(1):vdaa042. doi:10.1093/noajnl/vdaa042.

Anderson et al. Molecular and clonal evolution in recurrent metastatic gliosarcoma. Cold Spring Harb Mol Case Stud. 2020 Feb 3;6(1):a004671. doi: 10.1101/mcs.a004671.

Gromeier et al. Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. Nat Commun. 2021 Jan 13;12(1):352. doi:10.1038/s41467-020-20469-6.

Kumthekar et al. A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma. Sci Transl Med. 2021 Mar 10;13(584):eabb3945. doi:10.1126/scitranslmed.abb3945.

Garofano et al. Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021 Feb;2(2):141-156. doi:10.1038/s43018-020-00159-4.

Kocakavuk et al. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nat Genetics. 2021 Feb;2(2):141-156. doi:10.1038/s41588-021-00874-3.

Claus et al. Environmental and sex-specific molecular signatures of glioma causation. Neuro Oncol. 2021 May 4;noab103. 10.1093/neuonc/noab103.

Wu et al. Metabolic expression profiling stratifies diffuse lower-grade glioma into three distinct tumour subtypes. Br J Cancer. 2021 Jul;125(2):255-264.doi: 10.1038/s41416-021-01418-6.

Liu et al. Global DNA methylation profiling reveals chromosomal instability in IDH-mutant astrocytomas. Acta Neuropathol Commun. 2022 Mar 9;10(1):32. doi: 10.1186/s40478-022-01339-2.

Wu et al. Natural coevolution of tumor and immunoenvironment in glioblastoma. Cancer Discov. 2022 Sep 19:CD-22-0196. doi: 10.1158/2159-8290.CD-22-0196.

Kashani et al. Integrated longitudinal analysis of adult grade 4 diffuse gliomas with long-term relapse interval revealed upregulation of TGF-β signaling in recurrent tumors.Neuro Oncol. 2022 Sep 17:noac220. doi: 10.1093/neuonc/noac220.

Sun S et al. Molecular and clinical characterization of PTRF in glioma via 1,022 samples. BMC Cancer. 2023 Jun 16;23(1):551. doi: 10.1186/s12885-023-11001-2.

Kocakavuk E et al. Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas. Neuro Oncol. 2023 Sep 5;25(9):1721-1723. doi: 10.1093/neuonc/noad095.

Andrieux G et al. Spatially resolved transcriptomic profiles reveal unique defining molecular features of infiltrative 5ALA-metabolizing cells associated with glioblastoma recurrence. Genome Med. 2023 Jul 11;15(1):48. doi: 10.1186/s13073-023-01207-1.

Jeon HM et al. Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling. Cancer Cell. 2023 Aug 14;41(8):1480-1497.e9. doi: 10.1016/j.ccell.2023.06.007.

Fabro F et al. Genomic Exploration of Distinct Molecular Phenotypes Steering Temozolomide Resistance Development in Patient-Derived Glioblastoma Cells. Int. J. Mol. Sci. 2023, 24(21), 15678;

Mu Q et al. Identifying predictors of glioma evolution from longitudinal sequencing. Sci Transl Med. 2023 Oct 4;15(716):eadh4181. doi: 10.1126/scitranslmed.adh4181.

Rautajoki KJ et al. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting. Acta Neuropathol Commun. 2023 Nov 6;11(1):176. doi: 10.1186/s40478-023-01669-9.